Opus Genetics Stock Performance
| IRD Stock | 2.47 0.03 1.20% |
On a scale of 0 to 100, Opus Genetics holds a performance score of 7. The company holds a Beta of 0.45, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Opus Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Opus Genetics is expected to be smaller as well. Please check Opus Genetics' value at risk, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Opus Genetics' historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Opus Genetics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Opus Genetics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.93 | Five Day Return 20.19 | Year To Date Return 17.92 | Ten Year Return 93.8 | All Time Return 93.8 |
Last Split Factor 1:4 | Dividend Date 2020-11-06 | Last Split Date 2020-11-06 |
1 | Analysts Estimate Alvotech to Report a Decline in Earnings What to Look Out for | 11/05/2025 |
2 | Opus Genetics to Participate in Upcoming Investment Conferences | 11/20/2025 |
3 | Disposition of 4000000 shares by Foundation Fighting Blindness Retinal Degeneration Fund of Opus Genetics, at 2.15 subject to Rule 16b-3 | 12/09/2025 |
4 | B.Riley initiates Opus Genetics stock with Buy rating on gene therapy potential By Investing.com - Investing.com South Africa | 12/10/2025 |
5 | Insider Selling Opus Genetics Director Sells 4,000,000 Shares of Stock | 12/12/2025 |
6 | Why Opus Genetics Inc. stock is a value investor pick - Portfolio Gains Summary AI Powered Market Entry Ideas - | 12/18/2025 |
7 | Acquisition by Gallagher Cam of 83000 shares of Opus Genetics at 1.9689 subject to Rule 16b-3 | 12/29/2025 |
8 | Acquisition by Ainsworth Sean of 42507 shares of Opus Genetics at 1.99 subject to Rule 16b-3 | 12/31/2025 |
9 | Acquisition by Gallagher Cam of 67000 shares of Opus Genetics subject to Rule 16b-3 | 01/06/2026 |
10 | Disposition of 50 shares by Zaremba Rabourn Amy of Opus Genetics at 1.93 subject to Rule 16b-3 | 01/09/2026 |
11 | Opus Genetics Highlights Gene Therapy Strategy at JPM Conference - TipRanks | 01/12/2026 |
12 | Disposition of 3390 shares by Zaremba Rabourn Amy of Opus Genetics at 2.1 subject to Rule 16b-3 | 01/16/2026 |
13 | Opus Genetics Stock Rating Upgraded by BTIG Research - MarketBeat | 01/21/2026 |
| Begin Period Cash Flow | 50.5 M | |
| Total Cashflows From Investing Activities | 1.2 M |
Opus Genetics Relative Risk vs. Return Landscape
If you would invest 200.00 in Opus Genetics on October 25, 2025 and sell it today you would earn a total of 46.50 from holding Opus Genetics or generate 23.25% return on investment over 90 days. Opus Genetics is generating 0.4386% of daily returns assuming volatility of 4.4456% on return distribution over 90 days investment horizon. In other words, 39% of stocks are less volatile than Opus, and above 92% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Opus Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Opus Genetics, and traders can use it to determine the average amount a Opus Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Opus Genetics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Opus Genetics by adding it to a well-diversified portfolio.
Opus Genetics Fundamentals Growth
Opus Stock prices reflect investors' perceptions of the future prospects and financial health of Opus Genetics, and Opus Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Opus Stock performance.
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 133.7 M | ||||
| Shares Outstanding | 68.96 M | ||||
| Price To Book | 27.39 X | ||||
| Price To Sales | 11.12 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) | ||||
| EBITDA | (57.52 M) | ||||
| Net Income | (57.53 M) | ||||
| Total Debt | 18.84 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (25.58 M) | ||||
| Earnings Per Share | (1.86) X | ||||
| Market Capitalization | 162.76 M | ||||
| Total Asset | 36.86 M | ||||
| Retained Earnings | (139 M) | ||||
| Working Capital | 25.32 M | ||||
About Opus Genetics Performance
By analyzing Opus Genetics' fundamental ratios, stakeholders can gain valuable insights into Opus Genetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Opus Genetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Opus Genetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (2.79) | (2.65) | |
| Return On Assets | (1.40) | (1.47) | |
| Return On Equity | (9.84) | (9.35) |
Things to note about Opus Genetics performance evaluation
Checking the ongoing alerts about Opus Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Opus Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Opus Genetics had very high historical volatility over the last 90 days | |
| Opus Genetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 10.99 M. Reported Net Loss for the year was (57.53 M) with loss before taxes, overhead, and interest of (12.79 M). | |
| Opus Genetics generates negative cash flow from operations | |
| Opus Genetics has a poor financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Opus Genetics Stock Rating Upgraded by BTIG Research - MarketBeat |
- Analyzing Opus Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Opus Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Opus Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Opus Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Opus Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Opus Genetics' stock. These opinions can provide insight into Opus Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |